128 related articles for article (PubMed ID: 33338262)
1. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes.
Hempel Sullivan H; Maynard JP; Heaphy CM; Lu J; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
J Pathol; 2021 Apr; 253(4):415-426. PubMed ID: 33338262
[TBL] [Abstract][Full Text] [Related]
2. High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes.
Hempel Sullivan H; Heaphy CM; Kulac I; Cuka N; Lu J; Barber JR; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):668-675. PubMed ID: 31932412
[TBL] [Abstract][Full Text] [Related]
3. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
4. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
[TBL] [Abstract][Full Text] [Related]
5. Immune cell infiltrates and prognosis in localized prostate cancer
Sfanos KS
J Pathol; 2022 Feb; 256(2):135-138. PubMed ID: 34694014
[TBL] [Abstract][Full Text] [Related]
6. Tumor infiltrating B-cells are increased in prostate cancer tissue.
Woo JR; Liss MA; Muldong MT; Palazzi K; Strasner A; Ammirante M; Varki N; Shabaik A; Howell S; Kane CJ; Karin M; Jamieson CA
J Transl Med; 2014 Jan; 12():30. PubMed ID: 24475900
[TBL] [Abstract][Full Text] [Related]
7. Mast cell phenotype in benign and malignant tumors of the prostate.
Globa T; Saptefrţi L; Ceauşu RA; Gaje P; Cimpean AM; Raica M
Pol J Pathol; 2014 Jun; 65(2):147-53. PubMed ID: 25119176
[TBL] [Abstract][Full Text] [Related]
8. Mast Cells in the Tumor Microenvironment.
Aponte-López A; Muñoz-Cruz S
Adv Exp Med Biol; 2020; 1273():159-173. PubMed ID: 33119881
[TBL] [Abstract][Full Text] [Related]
9. Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.
Hempel HA; Cuka NS; Kulac I; Barber JR; Cornish TC; Platz EA; De Marzo AM; Sfanos KS
Prostate; 2017 Mar; 77(4):412-424. PubMed ID: 27868214
[TBL] [Abstract][Full Text] [Related]
10. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer.
Nonomura N; Takayama H; Nishimura K; Oka D; Nakai Y; Shiba M; Tsujimura A; Nakayama M; Aozasa K; Okuyama A
Br J Cancer; 2007 Oct; 97(7):952-6. PubMed ID: 17848955
[TBL] [Abstract][Full Text] [Related]
11. Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression.
Schafer CC; Jiang J; Elsamanoudi S; Nousome D; Young DY; Song Y; Sesterhenn IA; Chesnut GT; Tan SH
Cancer Res Commun; 2023 Aug; 3(8):1423-1434. PubMed ID: 37534375
[TBL] [Abstract][Full Text] [Related]
12. Human C1q Tumor Necrosis Factor 8 (CTRP8) defines a novel tryptase+ mast cell subpopulation in the prostate cancer microenvironment.
Krishnan SN; Thanasupawat T; Arreza L; Wong GW; Sfanos K; Trock B; Arock M; Shah GG; Glogowska A; Ghavami S; Hombach-Klonisch S; Klonisch T
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166681. PubMed ID: 36921737
[TBL] [Abstract][Full Text] [Related]
13. Tissue engineered human prostate microtissues reveal key role of mast cell-derived tryptase in potentiating cancer-associated fibroblast (CAF)-induced morphometric transition in vitro.
Pereira BA; Lister NL; Hashimoto K; Teng L; Flandes-Iparraguirre M; Eder A; Sanchez-Herrero A; Niranjan B;
Biomaterials; 2019 Mar; 197():72-85. PubMed ID: 30641266
[TBL] [Abstract][Full Text] [Related]
14. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
Jachetti E; Cancila V; Rigoni A; Bongiovanni L; Cappetti B; Belmonte B; Enriquez C; Casalini P; Ostano P; Frossi B; Sangaletti S; Chiodoni C; Chiorino G; Pucillo CE; Tripodo C; Colombo MP
Cancer Immunol Res; 2018 May; 6(5):552-565. PubMed ID: 29523597
[TBL] [Abstract][Full Text] [Related]
15. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
Pittoni P; Tripodo C; Piconese S; Mauri G; Parenza M; Rigoni A; Sangaletti S; Colombo MP
Cancer Res; 2011 Sep; 71(18):5987-97. PubMed ID: 21896641
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.
Xu W; Qian J; Zeng F; Li S; Guo W; Chen L; Li G; Zhang Z; Wang QJ; Deng F
J Exp Clin Cancer Res; 2019 Mar; 38(1):114. PubMed ID: 30841931
[TBL] [Abstract][Full Text] [Related]
17. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
18. A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.
Ellem SJ; Taylor RA; Furic L; Larsson O; Frydenberg M; Pook D; Pedersen J; Cawsey B; Trotta A; Need E; Buchanan G; Risbridger GP
J Pathol; 2014 Sep; 234(1):86-98. PubMed ID: 25042571
[TBL] [Abstract][Full Text] [Related]
19. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
[TBL] [Abstract][Full Text] [Related]
20. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
